Talk:Sinopharm BIBP COVID-19 vaccine

Skip to table of contents

This is the talk page for discussing improvements to the Sinopharm BIBP COVID-19 vaccine article.
This is not a forum for general discussion of the article's subject.

Put new text under old text. Click here to start a new topic.
New to Wikipedia? Welcome! Learn to edit; get help.

Article policies

Find medical sources: Source guidelines · PubMed · Cochrane · DOAJ · Gale · OpenMD · ScienceDirect · Springer · Trip · Wiley · TWL

Archives: Index, 1: 3 months

The contentious topics procedure applies to this page. This page is related to COVID-19, broadly construed, which has been designated as a contentious topic.

Editors who repeatedly or seriously fail to adhere to the purpose of Wikipedia, any expected standards of behaviour, or any normal editorial process may be blocked or restricted by an administrator. Editors are advised to familiarise themselves with the contentious topics procedures before editing this page.

This article is written in British English, which has its own spelling conventions (colour, travelled, centre, defence, artefact, analyse) and some terms that are used in it may be different or absent from other varieties of English. According to the relevant style guide, this should not be changed without broad consensus.

COVID-19 Mid‑importance

	COVID-19 portal This article is within the scope of WikiProject COVID-19, a project to coordinate efforts to improve all COVID-19-related articles. If you would like to help, you are invited to join and to participate in project discussions.COVID-19Wikipedia:WikiProject COVID-19Template:WikiProject COVID-19COVID-19 articles
Mid	This article has been rated as Mid-importance on the project's importance scale.

Medicine Mid‑importance

	Medicine portal This article is within the scope of WikiProject Medicine, which recommends that medicine-related articles follow the Manual of Style for medicine-related articles and that biomedical information in any article use high-quality medical sources. Please visit the project page for details or ask questions at Wikipedia talk:WikiProject Medicine.MedicineWikipedia:WikiProject MedicineTemplate:WikiProject Medicinemedicine articles
Mid	This article has been rated as Mid-importance on the project's importance scale.

Pharmacology Mid‑importance

	This article is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.PharmacologyWikipedia:WikiProject PharmacologyTemplate:WikiProject Pharmacologypharmacology articles
Mid	This article has been rated as Mid-importance on the project's importance scale.

China Mid‑importance

	China portal This article is within the scope of WikiProject China, a collaborative effort to improve the coverage of China related articles on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.ChinaWikipedia:WikiProject ChinaTemplate:WikiProject ChinaChina-related articles
Mid	This article has been rated as Mid-importance on the project's importance scale.

It is requested that a biochemistry diagram or diagrams be included in this article to improve its quality. Specific illustrations, plots or diagrams can be requested at the Graphic Lab.
For more information, refer to discussion on this page and/or the listing at Wikipedia:Requested images.

It is requested that a logo be included in this article to improve its quality.
For more information, refer to discussion on this page and/or the listing at Wikipedia:Requested images. The Free Image Search Tool may be able to locate suitable images on Flickr and other web sites.

Upload

Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Sinopharm BIBP COVID-19 vaccine.

PubMed provides review articles from the past five years (limit to free review articles)
The TRIP database provides clinical publications about evidence-based medicine.
Other potential sources include: Centre for Reviews and Dissemination and CDC

On 12 August 2021, it was proposed that this article be moved to Sinopharm COVID-19 vaccine BIBP. The result of the discussion was Moved to Sinopharm BIBP COVID-19 vaccine and Sinopharm WIBP COVID-19 vaccine.

Requested move 12 August 2021

The following is a closed discussion of a requested move. Please do not modify it. Subsequent comments should be made in a new section on the talk page. Editors desiring to contest the closing decision should consider a move review after discussing it on the closer's talk page. No further edits should be made to this discussion.

The result of the move request was: Moved to Sinopharm BIBP COVID-19 vaccine and Sinopharm WIBP COVID-19 vaccine. per discussion consensus and consistency policies. (non-admin closure) — Shibbolethink ^(♔ ^♕) 15:22, 26 August 2021 (UTC)[reply]

– Following WP:MEDTITLE and WP:MEDORG, the World Health Organization seems to prefer Sinopharm BIBP[1] and Sinopharm WIBP[2] over BBIBP/BBIBP-CorV and WIBP-CorV. English-speaking media mostly uses Sinopharm vaccine, ignoring the existence of WIBP-CorV. If this request is approved, then naturally WIBP-CorV would be moved to Sinopharm COVID-19 vaccine WIBP for consistency. Fernando Trebien (talk) 20:27, 12 August 2021 (UTC) — Relisting. D🐶ggy54321 ^{(let's chat!)} 21:16, 19 August 2021 (UTC)[reply]

Comment. I think Sinopharm BIBP COVID-19 vaccine and Sinopharm WIBP COVID-19 vaccine would be more more consistent with how other vaccines are named within Wikipedia. No need to split up the two parts of each name. John P. Sadowski (NIOSH) (talk) 03:30, 14 August 2021 (UTC)[reply]
Weak move to Sinopharm BIBP COVID-19 vaccine and Sinopharm WIBP COVID-19 vaccine. I have no problems with the current title, but if I have to choose, John P. Sadowski (NIOSH)'s suggestion the best way to go. —hueman1 (talk • contributions) 13:23, 14 August 2021 (UTC)[reply]
Comment. Sinopharm BIBP COVID-19 vaccine and Sinopharm WIBP COVID-19 vaccine seem ok to me. --Fernando Trebien (talk) 15:30, 14 August 2021 (UTC)[reply]
Support per John P. Sadowski (NIOSH). Abrilando232 (talk) 23:00, 14 August 2021 (UTC)[reply]
Relisting comment: there seems to be a consensus that Sinopharm BIBP COVID-19 vaccine and Sinopharm WIBP COVID-19 vaccine are both good alternative titles, and I am relisting so the discussion can be more focused on which of the two potential suggestions I just listed would be a better title for the page. Thanks! D🐶ggy54321 ^{(let's chat!)} 21:16, 19 August 2021 (UTC)[reply]
support per John P. Sadowski--Ozzie10aaaa (talk) 01:23, 22 August 2021 (UTC)[reply]
Note: WikiProject COVID-19 has been notified of this discussion. — Shibbolethink ^(♔ ^♕) 02:04, 20 August 2021 (UTC)[reply]

Note: WikiProject China has been notified of this discussion. — Shibbolethink ^(♔ ^♕) 02:05, 20 August 2021 (UTC)[reply]

Note: WikiProject Medicine has also been notified of this discussion. 2409:4061:700:93AF:418E:4466:2FDB:DC48 (talk) 19:20, 21 August 2021 (UTC)[reply]
I support moving the pages to Sinopharm BIBP COVID-19 vaccine and Sinopharm WIBP COVID-19 vaccine. WhatamIdoing (talk) 18:23, 22 August 2021 (UTC)[reply]

The discussion above is closed. Please do not modify it. Subsequent comments should be made on the appropriate discussion page. No further edits should be made to this discussion.

Semi-protected edit request on 10 September 2021

This edit request has been answered. Set the |answered= or |ans= parameter to no to reactivate your request.

change "emergency used authorization" to "emergency use authorization" 2001:EE0:1A1:5484:7280:4C94:88BE:3F67 (talk) 18:14, 10 September 2021 (UTC)[reply]

Done Extraordinary Writ (talk) 04:59, 11 September 2021 (UTC)[reply]

Wrong information

Authorizations . . . On 5 May 2021, EMA's human medicines committee (CHMP) has started a rolling review of the vaccine. The EU applicant for this medicine is the Italian company Life'On S.r.l.[84]

There is no ongoing EMA Rolling Review for Sinopharm BIBP-CorV. The information stated in literature reference 84 relates to the vaccine CoronaVac from SinoVac. --Benedikt.ebli (talk) 19:38, 2 February 2022 (UTC)[reply]

Antibody Response to Sinopharm COVID-19 Vaccine in Cancer Patients:

[In 2021, a cross-sectional study was conducted on 74 patients with various types of cancers in Iran. These patients had received two doses of the Sinopharm vaccine. The study measured levels of SARS-CoV-2 neutralizing antibodies, Anti-RBD, and Anti-Spike IgG for 4 to 6 weeks after the second vaccine dose. Positive neutralizing antibody status was observed in 41 individuals (55.4%). Additionally, 31 people (41.9%) tested positive for antibodies against RDB antigen, and 20 people (27%) had antibodies against Spike virus antigen. ref: https://jmums.mazums.ac.ir/article-1-20689-en.html] Reza nava (talk) 16:40, 2 May 2024 (UTC)[reply]